Comparing PET Imaging Options to Predict Cognitive Decline

June 24, 2015

For patients in the very early stages of mild cognitive impairment, prognosis can be gauged with PET imaging using two different tracers — fluorodeoxyglucose (FDG) and florbetapir, which measures beta-amyloid pathology — according to new research reported here at the Society of Nuclear Medicine and Molecular Imaging 2015 Annual Meeting.

"If you're looking across the broad range of levels of impairment, FDG may better predict how fast one will decline, but if you're looking specifically at a very minimally impaired group, amyloid may be a better way to separate out who is going to decline faster," said Jooyeon Lee, from the David Geffen School of Medicine at the University of California, Los Angeles.